News Innovent in line for $10.5bn in Pfizer cancer alliance Pfizer has signed a strategic-level alliance with Innovent, worth $10.5bn and spanning 12 cancer assets, in another sign of China's rising R&D status.
News Lilly strikes $8.8bn-plus alliance with China's Innovent Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.
News Innovent gets OK for China's first home-grown IL-23p19 drug Innovent has picked up approval in China for Pecondle, its anti-IL-23p19 antibody, as a treatment for moderate-to-severe plaque psoriasis.
News Innovent files high-dose mazdutide for obesity in China Innovent has filed a new high-strength version of its weight-loss drug mazdutide in China, aiming to help people with severe obesity.
News Pressure rises on Novo as Innovent drug tops Ozempic Innovent's dual glucagon and GLP-1 agonist mazdutide outperforms Novo Nordisk's Ozempic in overweight people with diabetes.
News Takeda builds in cancer with monster $11.4bn Innovent deal Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.